Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Abstract

Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes mellitus.